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Abstract
OBJECTIVE: To investigate the effect of the tradi-
tional Chinese herbs Astragali and Angelicae Sinen-
sis (A & As) particle [contains Huangqi (Radix Astrag-
ali Mongolica), Danggui (Radix Angelicae Sinensis),
Huzhanggeng (Rhizoma Polygoni Cuspidati) and
Danshen (Radix Salviae Miltiorrhizae)] on protein-
uria in glomerulonephritis patients with stage 2
chronic kidney disease.
METHODS: A prospective, multi-center, and ran-
domized controlled clinical trial was performed for
24 weeks. From March 2011 to April 2012, 158 pa-
tients from nine hospitals in China participated.
They were randomized into the A&As group (79 cas-
es, A&As particle 15.2 g/day) and losartan group
(79 cases, losartan 50 mg/day). At each follow-up
visit, clinical data including blood pressure, urinaly-
sis, 24-h-urinary protein excretion, serum albumin
and serum creatinine were collected.
RESULTS: All 158 patients completed the fol-
low-up. Proteinuria in the losartan group exhibited
a biphasic time-dependent decline with a signifi-
cant steady reduction from baseline to week 12
(P = 0.0014), and a platform level during the remain-
ing 12-week follow-up (P > 0.05). In contrast, there
was a continual significant decrease of proteinuria
in the A & As group (P < 0.001). When compared
with the losartan results, proteinuria in the A & As
group from week 16 to week 24 was significantly re-
duced (P < 0.001). Stable eGFRs and blood pressure
were also observed in both groups. Medication
side effects were minimal and non-fatal.
CONCLUSION: For Chinese glomerulonephritis pa-
tients with stage 2 chronic kidney disease, therapy
with A & As particles may provide effective anti-pro-
teinuria treatment.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Globally, chronic kidney disease (CKD) has been in-
creasing. In China, the prevalence of CKD in adults is
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more than 10%,1,2 and unlike in developed countries,
primary glomerulonephritis (GN) rather than hyper-
tensive nephropathy and diabetic nephropathy is the
leading cause of end-stage renal disease.3,4 For CKD, it
is critical to slow down the progression of stage 2, be-
cause renal disorder could accelerate beyond this stage.5,6
Therefore, a major challenge for Chinese nephrologist
is to delay the progression of GN with stage 2 CKD.
Proteinuria is recognized as an independent risk factor
for progression of GN.7 Corticosteroid and other im-
munosuppresants are cornerstone therapies for protein-
uria. Nevertheless, these drugs are not indicative for
many GN patients with stage 2 CKD. Instead, angio-
tensin Ⅱ type 1 receptor blockers (ARBs) and/or an-
giotensin converting enzyme (ACE) inhibitors play im-
portant roles in the treatment of proteinuria.8 Howev-
er, the therapeutic effect of renin-angiotensin system
blockade is not always satisfactory for Chinese GN pa-
tients with stage 2 CKD. Many of these patients, who
are normotensive, cannot tolerate even moderate dosag-
es of ARBs and/or ACE inhibitors because of systemic
hypotension.9 This condition is particularly common
in Chinese patients, especially in the early stages of
CKD. In addition, a higher dosage of ARBs and/or
ACE inhibitors does not exert an incremental nephro-
protective response.9-11 Therefore, it is essential to ex-
plore other alternative therapeutic approaches.
In Asian countries including China, Traditional Chi-
nese Medicines (TCM) have long been used to treat
proteinuria.12,13 Based on the personal experiences of ex-
perts from different regions in China, patients with
GN have been treated with different herb formula-
tions. Although the therapeutic effect of these on pro-
teinuria has been demonstrated in animal studies, only
a few small single-center retrospective studies have
been published. The formulation of Astragali and An-
gelicae Sinensis (A & As) particle [contains Huangqi
(Radix Astragali Mongolica), Danggui (Radix Angelicae
Sinensis), Huzhanggeng (Rhizoma Polygoni Cuspidati)
and Danshen (Radix Salviae Miltiorrhizae)] was devel-
oped for the treatment of GN in the 1990s at Shu-
guang hospital which is affiliated to Shanghai Universi-
ty of TCM. There are four herbs selected in the A &
As particle, which are based on the theory of TCM and
on extensive experience from senior physicians over sev-
eral decades who have used traditional Chinese medi-
cine to treat patients with GN. Of note, the A&As par-
ticle contains Astragali and Angelicae Sinensis, which
are known to reduce proteinuria.14,15 Several small clini-
cal studies showed that the A & As particle and its
components could improve proteinuria in patients
with GN.16,17 However, none of these individual herbs
have been tested in a large clinical trial.
To investigate the effect of A & As particles on protein-
uria in Chinese GN patients with stage 2 CKD, we per-
formed a prospective, multi-center and randomized
controlled clinical study using identical qualitative and
quantitative preparation. Our secondary objectives
were to observe A & As particle safety and tolerability.
MATERIALS ANDMETHODS
Selection and description of participants
The study recruited 158 patients from nine hospitals
in China (Shuguang Hospital affiliated to Shanghai
University of Traditional Chinese Medicine, Heilongji-
ang Academy of Traditional Chinese Medicine, Chi-
nese Medicine Hospital of Hubei Province, Putuo Hos-
pital affiliated to Shanghai University of Traditional
Chinese Medicine, Zhongshan Hospital affiliated to Fu-
Dan University, Yueyang Hospital affiliated to Shang-
hai University of Traditional Chinese Medicine, the
Fifth Hospital Affiliated to Zunyi Medical College,
Yangpu Hospital of Traditional Chinese Medicine, and
Yinhang Community Health Center). All patients were
clinically diagnosed with primary chronic glomerulone-
phritis.
Inclusion criteria for all recruits included the follow-
ing: (a) underwent renal biopsy, (b) diagnosed with
stage 2 CKD having a mild decrease of estimated glo-
merular filtration rate (eGFR) from 60 to 89 mL/min
per 1.73 m2 according to The National Kidney Founda-
tion Kidney Disease Outcomes Quality Initiative defi-
nition, (c) persistent stable non-nephrotic proteinuria
(0.5 to 2.5 g/day), (d) not taking ACE inhibitors and/
or ARBs, or having taken these drugs but after a wash-
out period, (e) normal blood pressure (an office blood
pressure of ≤ 130/80 mm Hg in the sitting position),
and (f ) age between 18 and 70 years.
Exclusion criteria included: (a) secondary etiology in-
cluding lupus, diabetes, and hypertension, (b) women
in pregnancy or lactation, (c) serious complications in-
cluding hematologic diseases, malignancy and infec-
tion, (d) acute kidney failure or renal allografts, (e)
known allergy to the study drugs, (f ) psychosis or unco-
operative, (g) enrolled in other clinical trials in the pre-
vious 3 months, and 8) treatment with steroids and/or
other immunosuppresants.
The study followed evidence-based principles and used
a prospective, multi-center and randomized controlled
design. Ethical guidelines were strictly conducted in ac-
cordance with the Declaration of Helsinki and with lo-
cal regulations. The protocol was approved by the re-
search ethics committee of Shuguang Hospital.
Two assessors monitored the study and were blinded to
the treatment groups. All participants were clearly in-
formed and provided written informed consent for par-
ticipation. The study sponsors provided the first avail-
able allocation number, which were assigned in consec-
utive order, to the enrolled patients from the nine
hospitals. The numbers of patients from each hospi-
tal were 18 each from Shuguang Hospital, Heilongji-
ang Academy of Traditional Chinese Medicine, Chi-
nese Medicine Hospital of Hubei Province, Putuo Hos-
pital, and Zhongshan Hospital, and 17 each from Yuey-
ang Hospital, Fifth Hospital Affiliated to Zunyi Medi-
cal College, Yangpu Hospital of Traditional Chinese
Medicine, and Yinhang Community Health Center.
300
JTCM |www. journaltcm. com June 15, 2016 |Volume 36 | Issue 3 |
Shen PC et al. / Clinical Study
Drug preparation
The formulation of A & As particle consisted of
Huangqi (Radix Astragali Mongolici) 15 g, Danggui
(Radix Angelicae Sinensis) 15 g, Huzhanggeng (Rhi-
zoma Polygoni Cuspidati) 15 g , and Danshen (Radix
Salviae Miltiorrhizae) 15 g. These traditional Chinese
herbs were processed into particles by Jiangyin Tianji-
ang Pharmaceutical Co., Ltd., (Jiangyin, China). The
particles were prepared by decoction, concentration,
and spray drying. The quality of A&As particles were
controlled rigorously according to good manufacturing
practice standards. The active constituents of tradition-
al Chinese herbs were analyzed by HPLC (Table 1).
Losartan tablets were purchased from MSD Pharma-
ceutical Co., Ltd., (Hangzhou, China). Besides, place-
bo tablets and placebo particles were also produced in
the two companies.
Interventions
Eligible patients were enrolled in a screening and wash-
out period (weeks -4 to 0) , then were assigned num-
bers consecutively. The study sponsors then dispensed
the study medications in sequentially numbered con-
tainers to the patients according to their assigned num-
ber. The patients had an equal probability of being as-
signed to A & As particle (A & As group) or to losar-
tan (losartan group). In addition, placebo tablets were
given to both groups of patients. All the patients and
observers were blinded to the assigned medication and
placebo interventions. Patients were instructed to take
the study medication (A & As particle 15.2 g/bag or
losartan 50 mg/tablet) orally once daily in the morn-
ing. Besides, placebo tablets were given to the patients
in A & As group, and placebo particles were also given
to the patients in losartan group.
Study sponsors monitored basic treatments between
groups, which were the same including diet and nutri-
tion consisting of daily protein intake (0.8 g/kg) with
high biological value protein > 50%, and daily calorie
intake (30-35 kcal/kg).
Measurements
All enrolled patients undertook follow-up visits once
every 4 weeks from week 4 to 24. After week 24, all pa-
tients continued to be followed up for another 8 weeks
but without their initial treatment plan. Clinical and
laboratory data were assessed at each visit. The clinical
data observed was blood pressure and laboratory data
including urinalysis, 24-h urinary protein excretion, se-
rum albumin, blood urea nitrogen, serum creatinine,
electrocardiogram and liver function test. At each visit,
adverse events were recorded. Drug consumption and
adherence were checked by counting pills. Patients
were considered adherent if at least 95% of the study
drug had been taken.
Urinary protein excretion was determined using 20%
sulfosalicylic acid at individual hospital laboratory. Se-
rum data were measured by standard laboratory tech-
niques and eGFR was calculated by using a modified
Modification of Diet in Renal Disease (MDRD) Study
equation based on data from Chinese CKD patients
[eGFR (mL·min－1·1.73 m－2) = 175 × Scr [mg/dl]−1.234
× age [year]−0.179 (female × 0.79)].18
Statistical analysis
All statistical analysis was done by SPSS software pro-
gram v13.0 (SPSS Inc., Chicago, IL, USA). All data
were expressed as mean ± standard deviation ( xˉ ± s).
The significance of differences between groups was ex-
amined using Student's t-test for unpaired data. Chang-
es from baseline to the last follow-up were compared
between the losartan and A & As groups using the t-test.
When differences could be demonstrated, values were
compared with the baseline using a paired-sample t-test.
Discrete data were examined using the Chi-squared
analysis. Clinical parameters were analyzed in both
groups by repeated-measures analysis of variance
(ANOVA). Two-way repeated-measures ANOVA were
used to compare the proteinuria variation between
baseline and follow-up visits in each group and the dif-
ferences in proteinuria between groups. Values of P <
0.05 were considered to indicate statistical significance.
Active constituent
Molecular formula
Extract from traditional
Chinese herb
Chromatography column
(mm×mm, μm)
Mobile phase
Column temperature (℃)
Detection wavelength (nm)
Number of theoretical plates
(peak calculation, n)
Content per bag (mg)
AstragalosideⅣ
C41H68O14
Radix Astragali
Shim-pack
octadecyl silane
(150 × 4.6, 5)
Acetonitrile
-water
20
203
4000
1.5
Ferulic acid
C10H10O4
Radix Angelicae
Sinensis
Dionex Acclaim120
C18
(250 × 4.6, 5)
1.5% glacial acetic
acid-methanol
35
320
5000
2
Emodin
C15H10O5
Rhizoma Polygoni
Cuspidati
Thermo octadecyl
silane Hypersil C_(18)
(250 × 4.6, 5)
0.1%aqueous acetic
acid-methanol
35
254
3000
13.5
Salvianolic acid B
C36H30O16
Radix Salviae Miltiorrhizae
Kinetex core-shell technology
(100 × 4.6, 2.6)
0.1% trifluoroacetic acid
aqueous solution-acetonitrile
30
286
2000
30
Table 1 Active constituents of the traditional Chinese herbs used in the Astragali and Angelica (A & As) particle
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RESULTS
Baseline characteristics
From March 2011 to April 2012, 158 screened pa-
tients satisfied the study criteria and were enrolled. All
patients were ethnic Chinese. Patients were randomly
allocated to either the A & As or losartan groups with
79 in each. All patients completed the study (Figure 1).
The mean age at baseline was (49.8 ± 10.5) years
(range 20 to 65 years). Baseline characteristics did not
significantly differ between the two groups (Table 2).
The primary histological type of all patients was IgA
nephropathy (IgAN, 57 cases). The remaining types in-
cluded mesangial proliferative glomerulonephritis
(MsPGN, 31 cases), focal segmental glomerular sclero-
sis (FSGS, 25 cases), minimal change disease (MCD,
17 cases), membranous nephropathy (MN, 15 cases),
IgM nephropathy (IgMN, 7 cases), and membranopro-
liferative glomerulonephritis (MPGN, 6 cases).
Table 2 Baseline characteristics in the Losartan and A & As groups ( xˉ ± s)
Parameter
Age (years)
Female/Male (n)
Body weight (kg)
SBP (mm Hg)
DBP (mm Hg)
Proteinuria (g/day)
Serum albumin (g/L)
Serum creatinine (mg/dL)
eGFR (mL·min－1·1.73m－2)
Hemoglobin (g/L)
Losartan (n=79)
50.82±10.33
37/42
61.67±11.21
119.64±10.75
78.38±9.89
1.37±0.52
39.11±4.26
1.09±0.27
73.88±8.17
115.92±13.39
A & As (n=79)
49.86±10.85
36/43
62.44±10.74
118.93±9.64
77.55±9.96
1.38±0.55
38.69±3.87
1.08±0.31
72.63±8.52
113.58±12.71
P value
0.89
0.79
0.71
0.66
0.61
0.93
0.43
0.83
0.37
0.25
Notes: A & As: Astragali and Angelica; SBP: systolic blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration
rate.
458 Patients screened
Excluded (n = 282)
Notmeeting inclusion criteria (n =231)
Refused to participate (n = 30)
Withdrew consent (n = 8)
Took excluded drug (n = 4)
Screening period too longer (n = 3)
Unacceptable medical history (n = 2)
Other reasons (n = 4)
176 enrolled and randomly assigned
88 allocated to receive losartan
(losartan group) 88 allocated to receive Astragali andAngelicae sinensis particle (A & As group)
Discontinued (n = 2)
Withdrew consent (n=1)
Lost to follow up (n = 1)
Pregnancy (n = 3)
Other reasons (n = 2)
Discontinued (n = 2)
Withdrew consent
(n = 1)
Lost to follow up (n = 2)
Pregnancy (n = 2)
Other reasons (n = 2)
Intention-to-treat analyzed (n = 79) Intention-to-treat analyzed (n = 79)
Figure 1 Enrollment and randomization of patients
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Effect on proteinuria
The proteinuria profile throughout the study period is
presented in Table 3 and Figure 2. There was a steady
decrease in the A & As group, while the losartan
group, in contrast, exhibited a biphasic time-depen-
dent decline from baseline to week 12 (P = 0.0014)
and a platform level during the remaining weeks 16 to
24 period (P > 0.05). The proteinuria in the A & As
group from week 16 to week 24 was significantly re-
duced compared with the losartan group (P < 0.05). Af-
ter treatment with A & As particles, 18 patients
(22.5%) achieved a reduction in proteinuria to the nor-
mal range (< 0.15 g/day). Conversely, in the losartan
group, the minimum proteinuria was 0.21 g/day.
With regard to the pathological types of GN, the an-
ti-proteinuria efficacy of A & As particles were ordered
as follows from the best to the worst: MCD and IgAN
without focal segmental sclerosis, MsPGN, MN,
FSGS, MPGN and IgAN with crescents.
Additionally, A & As and losartan therapies were with-
drawn after week 24 in the two groups until week 32.
An obvious increase in proteinuria occurred in 53 losar-
tan patients [67.9%, (1.3 ± 0.7) g/day] and in 30 A &
As patients [37.5%, (0.6 ± 0.6) g/day].
As shown in Table 3 and Figure 3, eGFR had a reduc-
tion trend in the losartan group (P = 0.173), but re-
mained constant in the A & As group (P = 0.31). Also,
the results of eGFR in the losartan group compared
with the A & As group were not significantly reduced
at each visit during the study period (P > 0.05).
Effects on other parameters
The blood pressure measurements for the two groups
are shown in Figure 4. During the 24-week period, no
patient was instructed to take additional antihyperten-
sive agents. Blood pressure was usually maintained at
normal levels in both the A & As and losartan groups
(Table 3). No difference in mean blood pressure reduc-
tion was observed between the two groups. A correla-
tion analysis was conducted between the changes in
blood pressure and the changes in proteinuria in the
losartan group (P = 0.18, r = 0.15) and the A & As
group (P = 0.09, r = 0.27). The changes in blood pres-
sure did not significantly correlate.
Table 3 Changes in clinical parameters in the Losartan and A & As groups ( xˉ ± s)
Parameter
SBP (mm Hg)
DBP (mm Hg)
Proteinuria (g/day)
Serum albumin (g/L)
Serum creatinine (mg/dL)
EGFR (mL·min－1·1.73m－2)
Hemoglobin (g/L)
Serum potassium (mmol/L)
Losartan group
Baseline
119.64±10.75
78.38±9.89
1.37±0.52
39.11±4.26
1.09±0.27
73.88±8.17
115.92±13.39
4.22±0.09
Week 24
118.53±11.22
77.54±8.83
0.98±0.75
38.94±3.91
1.12±0.29
71.94±9.26
112.65±12.17
4.24±0.12
aP value
0.53
0.59
< 0.001
0.76
0.50
0.17
0.11
0.32
A & As group
Baseline
118.93±9.64
77.55±9.96
1.38±0.55
38.69±3.87
1.08±0.31
72.63±8.52
113.58±12.71
4.23±0.08
Week 24
117.97±10.35
78.22±8.04
0.52±0.51
38.06±4.18
1.10±0.25
73.93±7.79
111.24±12.31
4.25±0.09
bP value
0.53
0.62
< 0.001
0.34
0.65
0.31
0.25
0.21
cP value
0.73
0.60
< 0.001
0.16
0.64
0.14
0.47
0.62
Notes: Losartan group treated with losartan; A & As group treated with A & As particle. A & As: Astragali and Angelica; SBP: systolic
blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate. aP: losartan, week 24 vs baseline; bP: A & As,
week 24 vs baseline; cP: A & As vs losartan at week 24.
2.5
2.0
1.5
1.0
0.5
0.0
0 4 8 12 16 20 24 28 32
Time point (week)Losartan A & As
Pro
tei
nu
ria
(g/
day
)
Figure 2 Changes in proteinuria in two groups
Losartan group treated with losartan; A & As group treated
with A & As particle. A & As: Astragali and Angelica. Protein-
uria decreased significantly during the administration of As-
tragali and Angelica particles (1.38 ± 0.55 g/day to 0.52 ±
0.51 g/day, P < 0.001) and losartan (1.37 ± 0.52 g/day to 0.98
± 0.75 g/day, P < 0.001). Conversely, the proteinuria from
week 16 to week 24 between the two groups was found to
differ significantly.
0 4 8 12 16 20 24
Time point (week)Losartan A & As
90
85
80
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65
60
55e
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Figure 3 Changes in estimated glomerular filtration rate in
the two groups
Losartan group treated with losartan; A & As group treated
with A & As particle. A & As: Astragali and Angelica.
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No significant changes were observed in the other labo-
ratory parameters in both groups during the study peri-
od (Table 4). Patients treated with either A & As parti-
cles or losartan had no difference in serum albumin lev-
els from baseline levels to the study end. Neither losar-
tan nor A & As particles affected serum potassium or
hemoglobin levels.
Adherence, tolerability and safety
There were no patients who dropped out or died dur-
ing the research period. Overall, the incidence of side
effects in the A & As group was lower than that in the
losartan group (losartan group, 9 events and A & As
group, 2 events; P = 0.03). The side effects in the losar-
tan group included dry cough (5 cases), hypotension
(2 cases), and liver function disorder (1 case). For the
two hypotensive patients, the losartan tablet of 50 mg
was divided into two equal dosages of 25 mg each and
given 12 h apart after which improvement was report-
ed in their symptoms. One case of gastrointestinal
symptoms occurred in A & As group and one case of
upper respiratory tract infection was reported in each
group.
DISCUSSION
Currently, the main treatments for proteinuria for GN
patients with stage 2 CKD are immunosuppresants
and/or ARBs/ACE inhibitors. However, they are associ-
ated with side effects, which offset the beneficial reno-
protective effects, and are usually restricted.19-21 As a re-
sult, patients may be intolerant and discontinue the
therapy, and thus lose valuable therapy time. In this
study, proteinuria was significantly decreased, and the
proteinuria in the A & As particle group was markedly
reduced from week 16 to week 24, as compared with
losartan (P < 0.05). As regards the magnitude of the de-
crease in proteinuria, nearly one-quarter of A & As pa-
tients achieved a complete remission (24-h urinary pro-
tein excretion<0.15g/day).Thus,A&Asparticles appear
to have a comparatively good anti-proteinuria effect.
The anti-proteinuria effect of A & As particles persist-
ed throughout the study protocol and increased with
time. However, losartan was associated with a biphasic
time-dependent reduction, i.e. a sustained decrease dur-
ing the early phase followed by a platform level during
the later phase. Additionally, after stopping the thera-
pies, proteinuria in more than two-thirds of the losar-
tan patients had nearly achieved their baseline levels,
but approximately 60% of the A & As patients re-
mained stable. Indications suggest that the anti-protein-
uria efficacy of A & As particle may be sustainable,not
only initially but persistently for some time. Patients
with consecutive mild proteinuria during treatment are
more liable to renal function deterioration than those
with substantial proteinuria at the beginning.7,22,23 Also,
when the reduction of proteinuria is greater during the
course of the disease, the likelihood of progression is
less. Although traditional Chinese herbs are relatively
safe at therapeutic doses, some can cause severe side ef-
fects including liver toxicity. In this study, there were
relatively few side effects and no liver injury occurred
in theA&As group, implying that it's safe and tolerable.
Therapeutic efficacy of TCM in treating CKD is main-
ly supported by the cumulative empiric experience, but
most of clinical TCM studies cannot be widely accept-
ed. In this study, only one unified predefined protocol
was applied at each center. According to our knowl-
edge, it is the first attempt to treat Chinese GN pa-
tients in CKD stage 2 in a multi-center, randomized
controlled, clinical study with a traditional Chinese
herbal formulation (A & As particle). The results of
this study indicate that in such patients, treatment
with TCM possesses the pronounced anti-proteinuria
efficacy, as well as good safety and tolerability.
The formulation of A & As particles contains four tra-
ditional Chinese herbs. Basic practice of TCM general-
ly consists of multiple drug therapy. It is generally be-
lieved that multiple herbal formulas are more effective
than a single herbal agent. The underlying anti-protein-
uria mechanism of A & As particles has not been exact-
ly clarified, but a series of relevant clinical and experi-
mental studies have been reported. Astragalus is report-
ed to improve proteinuria in CKD.14,24 It could attenu-
ate podocyte injury by regulating the expression and
distribution of nephrin and podocin. 25,26 In addition,
Huangqi (Radix Astragali Mongolici) and Danggui (Ra-
dix Angelicae Sinensis) are associated with fewer infiltra-
tion of macrophages and limitation of renal intrinsic
cell activation, which may lead to earlier and persistent
reduction of proteinuria.15,27 Dangshen (Radix Codonop-
sis) can alleviate glomerular injury by decreasing AngⅡ-induced PAl-1 and TGF-β1 secretion.28 Recently,
many promising active ingredients have been purified
from herbal extracts, which provide increased under-
standing of TCMs for targeting different pathways to
improve proteinuria. Astragaloside Ⅳ from Huangqi
(Radix Astragali Mongolici) exhibits regulation of the
140
120
100
80
60
40
20
0
0 2 4 6 8 10 12
Time point (month)
Losartan A & As
BP
(m
m
Hg
)
Figure 4 Changes in blood pressure in the losartan group
and A & As group
Losartan group treated with losartan; A & As group treated
with A & As particle. A & As: Astragali and Angelica. Systolic
blood pressure and diastolic blood pressure did not change
significantly in the two groups during the study period.
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immune system and anti-inflammation.29-32 Ferulic ac-
id, an active compound of Danggui (Radix Angelicae Si-
nensis), has been confirmed to ameliorate adenine-in-
duced kidney damage in rats.33 Emodin, an active com-
pound of Huzhanggen (Rhixoma Polygoni Cuspidati),
has a major role in inhibiting the differentiation and
maturation of dendritic cells, and increases the number
of regulatory T cells.34,35 These results indicate that A &
As particles have multiple mechanisms of action that
may contribute to its anti-proteinuria effect. More
thorough molecular mechanistic studies using modern
scientific methodology and approaches are needed.
In the present study, there was no clinical effect ob-
served on blood pressure, because the enrolled patients
were normotensive at study entry and during the study.
Therefore, we did not have to add extra antihyperten-
sive agents. These findings confirm that the anti-pro-
teinuria benefit observed in the A & As-treated group
might be attributed to a direct action, rather than
based on a reduction of systemic blood pressure. Al-
though the study period was relatively short, there was
no observed deterioration of renal function in the two
groups during the 24 week study period. This indicates
that the anti-proteinuric process was independent of
changes in eGFR. In addition, we collected data on the
level of serum albumin in these patients, to exclude
this parameter as the reason for the observed differenc-
es in proteinuria in both groups. The levels of serum al-
bumin were similar during the observational period, so
we could verify that the lower proteinuria in the pa-
tients who received A&As was not due to lower serum
albumin, i.e. lower albumin clearance.
Of the 158 biopsy-proven patients, the anti-protein-
uria efficacies of the A & As particles were positive in
MCD, IgAN without focal segmental sclerosis, and
MsPGN, but disappointing in FSGS, MPGN and
IgAN with crescents. However, this is consistent with
the clinical observation that MCD and MsPGN may
usually have an optimistic prognosis, while FSGS, MP-
GN and severe IgAN imply worse progression. Hence,
early establishment of diagnosis and timely appropriate
therapeutic intervention for CKD should be consid-
ered in order to improve prognosis.
There are several limitations to our research. First, the
study was of relatively short duration. Given the lack
of long-term data, the study could have been strength-
ened by a longer follow-up period to confirm whether
the superior renoprotective effect of the A & As parti-
cle could be sustainable. Second, because this study on-
ly involved Chinese patients, we do not know whether
this TCM therapy could also be applied to other ethnic
patients.
In summary, this study is the first prospective,
multi-center, and randomized controlled clinical study
of TCM for treating Chinese proteinuric GN patients
with stage 2 CKD. The results indicated that A & As
particles can improve proteinuria and notably without
significant side effects. Further investigations with lon-
ger follow-up are necessary to improve our understand-
ing that A & As particles may be a more effective sub-
stitute therapy for CKD.
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